Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182215 | 0.82 | TACR1 (0.41) | MGLLTACR1OPRD1NAMPTKCNH2 | |
| SCHEMBL19852075 | 0.82 | MGLL (0.37) | MGLLTACR1OPRD1NAMPTKCNH2 | |
| SCHEMBL18422847 | 0.81 | TACR1 (0.51) | MGLLTACR1OPRD1SMN1; SMN2NAMPT | |
| SCHEMBL20397239 | 0.78 | MGLL (0.70) | MGLLUSP2CYP2D6TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2422141 | 0.74 | SLC6A2 (0.44) | CYP2D6KCNH2 | |
| SCHEMBL20399225 | 0.72 | MGLL (0.71) | MGLL | |
| Hydrochloric Acid SCHEMBL2424034 | 0.72 | MAOB (0.42) | OPRD1KCNH2 | |
| Hydrochloric Acid SCHEMBL2427842 | 0.72 | MAOB (0.42) | OPRD1KCNH2 | |
| SCHEMBL19741202 | 0.71 | KCNH2 (0.41) | MGLLTSHRKDM1AKCNH2GRIA2 | |
| SCHEMBL18423505 | 0.71 | SLC6A3 (0.43) | MGLLTACR1OPRD1CYP2D6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018134698-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134698-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20160064669-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885TACR1 880/4885USP2 4880/4885 |
| US-20160064669-A1 | AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME | PNMT, TYR, AOC2 | MGLL 1836/4885TACR1 2874/4885USP2 4541/4885 |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885TACR1 880/4885USP2 4880/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | MGLL 16/4885TACR1 880/4885USP2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.